| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-03-13 | Ideaya Biosciences (USA - CA) | chief medical officer | nomination | Cancer - Oncology | Nomination | |
| 2018-03-13 | Ideaya Biosciences (USA - CA) Cancer Research UK (UK) | small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG) | development | Cancer - Oncology | Development agreement | |
| 2018-03-12 | Epizyme (USA - MA) | nomination | Cancer - Oncology - Rare diseases | Nomination | ||
| 2018-03-06 | Ligand Pharmaceuticals (USA - CA) Roivant Sciences (USA - CA) | LGD-6972 (now RVT-1502) | type 2 diabetes | licensing | Metabolic diseases | Licensing agreement |
| 2018-03-05 | Boehringer Ingelheim (Germany) ViraTherapeutics (Austria) | oncolytic virus therapy platform and VSV-GP (Vesicular Stomatitis Virus (VSV) glycoprotein (GP) | development | Cancer - Oncology | Development agreement | |
| 2018-03-05 | Retrotope (USA - CA) | vice president | nomination | Rare diseases - Genetic diseases - Neurological diseases | Nomination | |
| 2018-03-01 | Iovance Biotherapeutics (USA - CA) | member of the board of directors | nomination | Cancer - Oncology | Nomination | |
| 2018-02-28 | C3J Therapeutics (USA - CA) Synthetic Genomics (USA - CA) | engineered bacteriophage platform | multidrug-resistant bacterial infections | product acquisition | Infectious diseases | Product acquisition |
| 2018-02-26 | Mereo Biopharma (UK) | head of patient access and commercial planning | nomination | Rare diseases | Nomination | |
| 2018-02-22 | Kite Pharma (USA - CA) Sangamo Therapeutics (USA - CA) | ex vivo cell therapies in oncology using Sangamo's zinc finger nuclease (ZFN) technology platform | collaboration | Cancer - Oncology | Collaboration agreement | |
| 2018-02-21 | Amicus Therapeutics (USA - NJ) | member of the scientific advisory board | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2018-02-21 | Arix Bioscience (UK) Ipsen (France) | innovative therapies | undisclosed | development - commercialisation | undisclosed | Development agreement |
| 2018-02-20 | Voyager Therapeutics (USA - MA) Abbvie (USA - IL) | vectorized antibodies directed against tau | Alzheimer’s disease and other tau-related neurodegenerative diseases | development - commercialisation | Neurodegenerative diseases | Development agreement |
| 2018-02-20 | Minoryx Therapeutics (Spain) Gain Therapeutics (Switzerland) | Site-directed Enzyme Enhancement Therapy (SEE-Tx) platform | establishment of a new subsidiary in the EU | Technology - Services | Establishment of a new subsidiary in the EU | |
| 2018-02-19 | Arix Bioscience (UK) Fosun International (China) | undisclosed | development | undisclosed | Development agreement | |
| 2018-02-15 | Oxford Biomedica (UK) Bioverativ (USA - CA) | lentiviral vectors to treat haemophilia | hemophilia | licensing - collaboration | Rare diseases - Genetic diseases - Hematological diseases | Licensing agreement |
| 2018-02-12 | Sangamo Therapeutics (USA - CA) | senior vice president | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2018-02-12 | Roivant Sciences (Switzerland) Poxel (France) | imeglimin | type 2 diabetes | licensing | Metabolic diseases | Licensing agreement |
| 2018-02-12 | Axovant Sciences (USA - NY) | nomination | Neurological diseases - CNS diseases | Nomination | ||
| 2018-02-08 | Arbutus Biopharma (Canada) | hepatitis B | restructuring | Infectious diseases | Restructuring |
